Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In this ...

While trying to develop a comparatively easy, inexpensive way to give physicians and their patients with bladder cancer a better idea of likely outcome and best treatment options, scientists found ...

Urothelial cancer (UC) is the most common histology seen in bladder tumors. The 2022 WHO classification of urinary tract tumors includes a list of less common subtypes (formerly known as variants) for ...

“Incorporating ctDNA into the decision-making process helps refine who can safely keep their bladder,” Ghatalia, associate professor, Department of Hematology/Oncology, at Fox Chase Cancer Center in ...

Bladder cancer caught early is often amenable to treatment, but of course late-stage and aggressive characteristics alter the prognosis for the worse. Understanding high-risk features, including ...

Bladder EpiCheck® demonstrated superior performance to cytology alone with high sensitivity, specificity and NPV in a high-risk non-muscle invasive bladder cancer population undergoing instillations ...

Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience. Cabozantinib in patients with locally advanced ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...